



Onco-Life Cancer Centre Pvt. Ltd.

Hospital : Survey No. 252, Near Pune - Bangalore Highway, Shendre, Satara - 415 519

Reg. off: 11 B, B, Viceroy Park, Thakur Village, Kandivali (E), Mumbai - 400 101

Phone : (02162) 279091 / 92 / 93 / 94 ■ **Cell. :** 7769004343 / 7030362222.

Nuclear & PET / CT Scan : 7066223434.

Email : life@oncosol.com, ■ **Web :** www.oncolifehospitals.com

CIN No. : U93000MH2014PTC253216 ■ **GSTIN No. :** 27AABCO9689H1ZS




Date: 29.05.2026

Estimate Certificate

To,
Bloom One Foundation,
Mumbai

This is to certify that Master.Yadnesh Ajay Salunkhe Age – 3 Yrs., Male, is a case B cell acute lymphoblastic leukemia. He is on Chemo Therapy .He require intermittent admission Blood and Blood Product Transfusion, Bone Marrow Procedure. Total expenditure for this entire treatment is approximately Rs 2,00,000/-(Rs.Two lakh only) inclusive of Hospitalization, Medicines & Investigations.


This certificate has been issued Master. Yadnesh Ajay Salunkhe for the purpose of financial aid.


Dr. Vinod R. Patil
MD, DM (Clinical Hematology)
PDT - Bone Marrow Transplant
Reg.No.2009/03/1058
Consultant Hematologist,
Hematooncologist & BMT. Physician.
Onco-Life Cancer Centre Pvt. Ltd



महाराष्ट्र शासन

तहसील कार्यालय : कराड, जिल्हा : सातारा



जा क्रमांक : 42655657005

दिनांक : 15 एप्रिल 2026

उत्पन्न प्रमाणपत्र (1 वर्षासाठी)

प्रमाणित करण्यात येते की, श्री / श्रीमती अजय बाळकृष्ण साळुंखे राहणार वराडे गाव वराडे, तहसील कराड, जिल्हा सातारा येथील अर्जदार आहेत. त्यांचे तलाठी अहवालानुसार व त्यांनी पुरविलेल्या माहिती / कागदपत्रानुसार त्यांच्या कुटुंबातील सर्व सदस्यांचे सर्व मार्गांनी मिळालेले एक वर्षाचे उत्पन्न खालील प्रमाणे आहे

वर्ष	वार्षिक उत्पन्न (₹)	अक्षरी (रुपये)
2025 - 2026	60,000	साठ हजार

सदरचा दाखला श्री / श्रीमती अजय बाळकृष्ण साळुंखे यांना देण्यात येत आहे.
हे प्रमाणपत्र 31 मार्च 2027 पर्यंतच वैध राहील.



12512604145014165093

स्थळ : कराड

दिनांक : 15 एप्रिल 2026



(With the seal of Office)

Digitally signed by
Kalpana Dattatray Dhavale
Date: 2026-04-15 01:12:22 PM

तहसीलदार / नायब
तहसीलदार
कराड

Printed By -OMTID :MH033001101 VLE Name :Chetan Mahadev Babar, Date:15/04/2026 12:52PM

माहिती तंत्रज्ञान (मातं) अधिनियम, 2000 नुसार डिजिटल स्वाक्षरी असणारा हा दस्तऐवज कायदेशीररित्या वैध आहे.
पडताळणीसाठी - <https://aaplesarkar.mahaonline.gov.in> येथे भेट द्या.

भारत सरकार
Government of India

आधार
आधार

Issue Date : 06/10/2023

यज्ञेश अजय साळुंखे
Yadnesh Ajay Salunkhe
जन्म तारीख / DOB : 25/11/2022
पुरुष / Male

हे आधार धारकाच्या केवळ 5 वर्षांपर्यंत वैध आहे.

4429 1546 0326

माझे आधार, माझी ओळख

भारतीय विशिष्ट ओळख प्राधिकरण
Unique Identification Authority of India

आधार
AADHAAR

Print Date : 16/10/2023

पत्ता मार्फत: अजय साळुंखे, वराडे, सातारा,
महाराष्ट्र, 415109

Address: C/O: Ajay Salunkhe, Varade,
Satara, Maharashtra, 415109

4429 1546 0326

1947 help@uidai.gov.in www.uidai.gov.in

शुल्क.—मूळ पत्रिकेस वीस रुपये, दुय्यम पत्रिकेस चाळीस रुपये.



भारत सरकार

Government of India



अजय बाळकृष्ण साळुंखे

Ajay Balkrushna Salunkhe

जन्म तारीख / DOB : 21/04/1996

पुरुष / Male



9857 2289 5244

आधार - सामान्य माणसाचा अधिकार



भारतीय विशिष्ट ओळख प्राधिकरण
Unique Identification Authority of India

पत्ता मु वराडे पोस्ट उंब्रज, वराडे,
उंबरज, सातारा, महाराष्ट्र, 415109

Address: at varade post umbraj, Varade,
Umbraj, Satara, Maharashtra, 415109

9857 2289 5244



1800 300 1947



help@uidai.gov.in



www.uidai.gov.in

आयकर विभाग
INCOME TAX DEPARTMENT

भारत सरकार
GOVT. OF INDIA

SALUNKHE AJAY BALKRUSHNA
BALKRUSHNA ANANDRAO SALUNKHE

21/04/1996
Permanent Account Number
FWLPS0419H


Signature



12/12/2014

Patient Information	Specimen Information	Client/Doctor Information
Name : MasterYADNESH AJAY SALUNKHE	Visit ID : LST059456	Client Code : HLM0051
Age/Gender : 3 Y 0 M 28 D /Male	Collected : 22/Apr/2026 13:35	Client Name : HLM ONCO LIFE
MobileNo :	Received : 23/Apr/2026 12:26	CANCER CENTRE PVT.LTD SATA
UHID : LDAA05250845	Reported : 26/Apr/2026 01:59	Client Add. : SHENDARE
Address :	IP/OP/Barcode : 260300192	Client No. :
	Report Status : Final Report	Ref Doctor : Dr.SELF

Bone Marrow Aspirate , UNSTAINED BONE MARROW SMEAR

BONE MARROW ASPIRATION SMEAR REPORT

Clinical History: A case of B-ALL after induction chemotherapy.

CBC/Blood smear findings: Not available.

BM Biopsy findings: Awaited.

BM Smear findings:

Cellularity: Tiny normocellular bone marrow particles are seen. Smears are hemodiluted.

M:E ratio: 1:1

Erythropoiesis: Normoblastic erythroid hyperplasia is seen.

Granulopoiesis: Granulopoiesis is suppressed and there is shift to the right (?dilutional effect).

Lymphopoiesis: Lymphocytes = 32%; Blasts = 3%.

Megakaryopoiesis: Megakaryocytes are not seen (?dilutional effect).

Iron Staining: ---

Differential cell count (out of all nucleated cells):

Cell population	%	Cell population	%
Erythroid precursors	58	Basophils	-
Granulocytes and late precursors	7	Promonocytes	-
Promyelocytes	-	Monocytes	-
Blasts	3	Lymphocytes	32
Eosinophils	-	Plasma cells	-

Impression: Hemodiluted bone marrow aspirate smears showing erythroid hyperplasia and lymphocytosis (commensurate with the age of the patient). Blasts are 3%.

Advice: Please correlate clinically and with the results of MRD analysis.

*** End Of Report ***

Patient Information	Specimen Information	Client/Doctor Information
Name : MasterYADNESH AJAY SALUNKHE	Visit ID : LST059456	Client Code : HLM0051
Age/Gender : 3 Y 0 M 28 D /Male	Collected : 22/Apr/2026 13:35	Client Name : HLM ONCO LIFE
MobileNo :	Received : 23/Apr/2026 11:14	CANCER CENTRE PVT.LTD SATA
UHID : LDAA05250845	Reported : 24/Apr/2026 23:45	Client Add. : SHENDARE
Address :	IP/OP/Barcode : 260300192	Client No. :
	Report Status : Final Report	Ref Doctor : Dr.SELF

Flowcytometry for Minimal Residual Disease (MRD) for B-ALL , BONE MARROW

Clinical History: A case of B-ALL on treatment.

FCM immunophenotype at presentation:CD10 positive, CD19 positive (dim), CD20 positive (subset), CD22 positive, CD38 positive, cytoplasmic CD79a positive, HLA-DR positive and nuclear TdT positive. Aberrant expression of CD13 (dim) and CD117 (dim) is also observed (Test performed in another laboratory).

Technical Information:

Instrument/ Technology: BD FACS Lyric Flow Cytometer / multicolour flow cytometry (MFC) - 12 colours
Anticoagulant : EDTA
Sample type: Bone Marrow
Method: Bulk LyseWash-Stain
Gating strategy: 12 colour FCM using FSC-SSC / CD45-SSC / CD19-SSC
Panel of antibodies used: CD10, CD19, CD20, CD34, CD38, CD45, CD66c, CD73, CD81 and CD123

Bone marrow aspirate smear: Smears made from EDTA anticoagulated bone marrow sample are hemodiluted and show erythroid hyperplasia. Granulopoiesis is relatively suppressed. Blasts are ~3% and lymphocytes are ~30%. Megakaryocytes are not seen (?dilutional effect).

Flow cytometry findings:Flow cytometric immunophenotyping of the anticoagulated (EDTA) bone marrow sample shows viable events of 3,555,449. CD19 positive events in viable population are 3.89%. Using the panel of antibodies listed above, measurable residual disease (MRD) of 0.05% was detected which is above the clinically significant cut-off of 0.01%.

Total number of events/cells acquired: 3,746,350 cells.

FSC/SSC viable events: 3,555,449 events.

% of CD19+ events in total viable population: 3.89%

% of CD19+ events in Syto 16 positive population: 3.58%

Patient Information	Specimen Information	Client/Doctor Information
Name : MasterYADNESH AJAY SALUNKHE	Visit ID : LST059456	Client Code : HLM0051
Age/Gender : 3 Y 0 M 28 D /Male	Collected : 22/Apr/2026 13:35	Client Name : HLM ONCO LIFE
MobileNo :	Received : 23/Apr/2026 12:26	CANCER CENTRE PVT.LTD SATA
UHID : LDAA05250845	Reported : 26/Apr/2026 01:59	Client Add. : SHENDARE
Address :	IP/OP/Barcode : 260300192	Client No. :
	Report Status : Final Report	Ref Doctor : Dr.SELF

Dr. Amar Dasgupta

Dr. Amar Dasgupta
MD, PhD, FIICC, Senior
Consultant
Hematopathologist



This test has been performed at Lupin Diagnostics Laboratory, NRL MUMBAI National Reference Laboratory, Plot No.C-533, MIDC, TTC Industrial Area, Pawane,TURBHE,NAVI MUMBAI , 400705



Please check this logo in the center of the report paper for authenticity, if not found then contact us

Registered and Corporate Office:
Lupin Diagnostics Limited, 3rd Floor,
Kalpataru Inspire, Off W. E. Highway,
Santacruz (East), Mumbai-400 055, India.
CIN: U24100MH2011PLC214885

Onco - Life Cancer Centre Pvt. Ltd. Page 2 of 4
Survey No. 252, A/P Shendre,
Opp. Abhaysinhraje Institute of Technology,
Tal & Dist. Satara, Maharashtra - 415519
Phone: 02162-350063 / 7769004343 / 7030362222

Patient Information	Specimen Information	Client/Doctor Information
Name : MasterYADNESH AJAY SALUNKHE	Visit ID : LST059456	Client Code : HLM0051
Age/Gender : 3 Y 0 M 28 D /Male	Collected : 22/Apr/2026 13:35	Client Name : HLM ONCO LIFE
MobileNo :	Received : 23/Apr/2026 11:14	CANCER CENTRE PVT.LTD SATA
UHID : LDAA05250845	Reported : 24/Apr/2026 23:45	Client Add. : SHENDARE
Address :	IP/OP/Barcode : 260300192	Client No. :
	Report Status : Final Report	Ref Doctor : Dr.SELF

Results:

Measurable Residual disease (MRD): 0.05 %

Measurable Residual disease (MRD): Present

LOD (limit of detection) : 0.0006%

LOQ: (limit of quantification): 0.001%

Interpretative Note:

The role of MRD assessment in risk-adapted management of B-ALL patients is now well established and the same has become an integral part of current management strategies for this disease. Measurement of residual disease first in post-induction bone marrow sample and subsequently at later time points is performed for this purpose. Large studies have shown that an MRD <0.01% in post-induction bone marrow is indicative of better disease control and is associated with lower risk of relapse and better chances of cure. In contrast, MRD 0.1% or more is associated with poor prognosis. These patients require and benefit from intensification of the therapy. Therefore, an accurate measurement of MRD in a representative bone marrow sample is vital. Recovery of the marrow from the effects of the drugs is variable following induction therapy, often leading to aspiration of hemodiluted bone marrow samples. Technological factors too can compromise the representativeness of the sample, thereby increasing the chances of false negative results. Hence, sample quality is of prime importance and the results should be interpreted against this background.

If Values are marked with * , they are critical values.

*** End Of Report ***

Dr. Amar Dasgupta

Dr. Amar Dasgupta
MD, PhD, FIICC, Senior
Consultant
Hematopathologist



Patient Information	Specimen Information	Client/Doctor Information
Name : MasterYADNESH AJAY SALUNKHE	Visit ID : LST059456	Client Code : HLM0051
Age/Gender : 3 Y 0 M 28 D /M	Collected : 22/Apr/2026 13:31	Client Name : HLM ONCO LIFE
MobileNo :	Received : 23/Apr/2026 12:07	CANCER CENTRE PVT.LTD SATA
UHID : LDAA05250845	Reported : 27/Apr/2026 20:17	Client Add. : SHENDARE
Address :	IP/OP/Barcode : 260300192	Client No. :
	Report Status : Final Report	Ref Doctor : Dr.SELF

HISTOPATHOLOGY REPORT

TEST:	Bone marrow biopsy
BIOPSY NO:	NRL0001/16018/26

SPECIMEN:	BONE MARROW
------------------	-------------

GROSS:	Received 3 pieces of linear bony tissue, the longest one measures 1.3 cm in length. All were processed together.
---------------	--

MICROSCOPY:	Sections of bone marrow trephine biopsy pieces show a total of ~35 intertrabecular spaces. Bone trabeculae are normal. The bone marrow is predominantly normocellular (cellularity ~40%) with hypercellular patches. There is erythroid hyperplasia across the entire biopsy section with enhanced erythropoiesis in the hypercellular areas. Granulopoiesis is relatively suppressed but an orderly maturation process is seen. Blasts are not increased. Megakaryocytes are present in a fair number. Increased (grade 1-2/3) reticulin fibrosis is present.
--------------------	---

IMPRESSION/ DIAGNOSIS:	Post-induction (chemotherapy) reactive/regenerative erythroid hyperplasia. Blasts are not increased. Bone marrow is in morphological remission.
-------------------------------	---

ADVICE/ COMMENT:	Please correlate clinically, with bone marrow aspirate smear morphology (reported on 25-04-26) and with the results of measurable residual disease (MRD) studies (reported on 24-04-26).
-------------------------	--

*** End Of Report ***

Dr. Amar Dasgupta

Dr. Amar Dasgupta
MD, PhD, FIICC, Senior
Consultant
Hematopathologist

